Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N, Suntronwong N, Phowatthanasathian H, Yorsaeng R, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Klinfueng S, Sudhinaraset N, Poovorawan Y. Wanlapakorn N, et al. Among authors: wongsrisang l. Vaccine. 2022 May 20;40(23):3203-3209. doi: 10.1016/j.vaccine.2022.04.043. Epub 2022 Apr 18. Vaccine. 2022. PMID: 35465981 Free PMC article.
Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023.
Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Vichaiwattana P, Klinfueng S, Wongsrisang L, Thongmee T, Aeemjinda R, Khanarat N, Srimuan D, Thatsanathorn T, Yorsaeng R, Katanyutanon A, Thanasopon W, Bhunyakitikorn W, Sonthichai C, Angsuwatcharakorn P, Withaksabut W, Wanlapakorn N, Sudhinaraset N, Poovorawan Y. Chansaenroj J, et al. Among authors: wongsrisang l. Sci Rep. 2023 Sep 20;13(1):15595. doi: 10.1038/s41598-023-42754-2. Sci Rep. 2023. PMID: 37730917 Free PMC article.
SARS-CoV-2 Antibody Dynamics after COVID-19 Vaccination and Infection: A Real-World Cross-Sectional Analysis.
Yorsaeng R, Atsawawaranunt K, Suntronwong N, Kanokudom S, Chansaenroj J, Assawakosri S, Nilyanimit P, Aeemjinda R, Khanarat N, Wongsrisang L, Auphimai C, Vichaiwattana P, Klinfueng S, Thongmee T, Srimuan D, Thatsanathorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: wongsrisang l. Vaccines (Basel). 2023 Jun 30;11(7):1184. doi: 10.3390/vaccines11071184. Vaccines (Basel). 2023. PMID: 37515001 Free PMC article.
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S, Thongmee T, Vichaiwattana P, Auphimai C, Wongsrisang L, Srimuan D, Thatsanatorn T, Klinfueng S, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Yorsaeng R, et al. Among authors: wongsrisang l. Vaccine. 2022 Jan 24;40(3):524-530. doi: 10.1016/j.vaccine.2021.11.083. Epub 2021 Dec 3. Vaccine. 2022. PMID: 34893344 Free PMC article.
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.
Chansaenroj J, Suntronwong N, Kanokudom S, Assawakosri S, Yorsaeng R, Vichaiwattana P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Thongmee T, Auphimai C, Nilyanimit P, Wanlapakorn N, Sudhinaraset N, Poovorawan Y. Chansaenroj J, et al. Among authors: wongsrisang l. Vaccines (Basel). 2022 Jul 3;10(7):1071. doi: 10.3390/vaccines10071071. Vaccines (Basel). 2022. PMID: 35891235 Free PMC article.
Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year.
Kanokudom S, Chansaenroj J, Assawakosri S, Suntronwong N, Yorsaeng R, Wongsrisang L, Aeemjinda R, Vichaiwattana P, Klinfueng S, Thatsanathorn T, Honsawek S, Poovorawan Y. Kanokudom S, et al. Among authors: wongsrisang l. Vaccines (Basel). 2023 Nov 7;11(11):1693. doi: 10.3390/vaccines11111693. Vaccines (Basel). 2023. PMID: 38006025 Free PMC article.
COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron.
Suntronwong N, Yorsaeng R, Puenpa J, Auphimai C, Thongmee T, Vichaiwattana P, Kanokudom S, Duangchinda T, Chantima W, Pakchotanon P, Assawakosri S, Nilyanimit P, Klinfueng S, Wongsrisang L, Srimuan D, Thatsanatorn T, Sudhinaraset N, Wanlapakorn N, Poovorawan Y. Suntronwong N, et al. Among authors: wongsrisang l. Vaccines (Basel). 2022 Mar 3;10(3):391. doi: 10.3390/vaccines10030391. Vaccines (Basel). 2022. PMID: 35335023 Free PMC article.